An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Actuate Therapeutics (NASDAQ:ACTU) on Saturday announced encouraging results from a Phase 2 clinical trial testing its ...

Emotional turmoil and touching family warmth will rule the upcoming episodes of Days of Our Lives for the week of June 2, ...

Joe Walsh is the first Alzheimer's patient to be treated with an experimental nasal spray designed to reduce inflammation in ...

Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...